Takeda Pharmaceutical Company Limited Capital Reinvestment Ratio
Takeda Pharmaceutical Company Limited capital reinvestment ratio. Takeda Pharmaceutical Company Limited (TKDA) has a Capital Reinvestment Ratio of 0.60x as of December 2025, meaning it reinvests 1% of its operating cash flow (€373.25 Billion) in capital expenditures (€222.37 Billion). See Takeda Pharmaceutical Company Limited free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Takeda Pharmaceutical Company Limited (2017–2025)
Capital reinvestment ratio of Takeda Pharmaceutical Company Limited from 2017 to 2025. This chart tracks Takeda Pharmaceutical Company Limited's Capital Reinvestment Ratio across 9 annual periods. See Takeda Pharmaceutical Company Limited (TKDA) flexibility index to measure the company's free cash flow as a share of total liabilities.
Takeda Pharmaceutical Company Limited Capital Reinvestment Ratio by Year (2017–2025)
Takeda Pharmaceutical Company Limited capital reinvestment ratio by year from 2017 to 2025. For the full cash flow conversion analysis, see how efficiently does Takeda Pharmaceutical Company Limited generate cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.36x | €1.06 Trillion | €379.62 Billion | ▼ -46.5% |
| 2024 | 0.67x | €716.34 Billion | €480.73 Billion | ▲ +3.5% |
| 2023 | 0.65x | €977.16 Billion | €633.69 Billion | ▲ +490.9% |
| 2022 | 0.11x | €1.12 Trillion | €123.25 Billion | ▼ -0.2% |
| 2021 | 0.11x | €1.01 Trillion | €111.21 Billion | ▼ -42.0% |
| 2020 | 0.19x | €669.75 Billion | €127.08 Billion | ▼ -19.8% |
| 2019 | 0.24x | €328.48 Billion | €77.68 Billion | ▲ +33.4% |
| 2018 | 0.18x | €377.85 Billion | €67.00 Billion | ▼ -24.8% |
| 2017 | 0.24x | €261.36 Billion | €61.66 Billion | — |